News | Radiation Therapy | September 19, 2017

Varian to Showcase Latest Radiation Therapy Technologies and Software at ASTRO 2017

Highlights include Halcyon IMRT platform and HyperArc high-definition radiotherapy system

Varian to Showcase Latest Radiation Therapy Technologies and Software at ASTRO 2017

September 19, 2017 — Varian Medical Systems announced it will be demonstrating its new Halcyon platform and HyperArc high-definition radiotherapy (HDRT) at the 2017 American Society for Radiation Oncology (ASTRO) Annual Meeting, Sept. 24-27 in San Diego. The company also will host its Users Meeting on Sept. 23 prior to the ASTRO meeting.

The Halcyon platform helps simplify and enhance virtually every aspect of image-guided volumetric intensity modulated radiotherapy (IMRT), while HyperArc HDRT is an advanced type of radiosurgery treatment.

In addition to Halcyon and HyperArc, Varian will showcase these solutions for simplifying and increasing access to advanced cancer care:

  • Eclipse 15.5 featuring treatment planning for HyperArc HDRT, RapidPlan knowledge-based planning, multicriteria optimization (MCO), plus fast optimization and dose calculation;
  • Iterative cone beam computed tomography (CBCT) on the TrueBeam platform, which produces exceptionally high quality images, according to the company, for better visualization of soft tissue structures;
  • ProBeam proton therapy, configurable as single- or multi-room solutions featuring gantries that rotate a full 360 degrees, RapidScan high-speed pencil-beam scanning for single-breath-hold lung SBPT and iterative CBCT for enhanced soft tissue resolution; and
  • Varian Marketplace, a digital marketplace for Varian and customer apps and software product extensions to solve real-world clinical and operational problems.

The Varian Users Meeting will provide attendees with new insights on the latest Varian technology. Topics include:

  • Early experience with the Halcyon system;
  • Multicriteria optimization and high-performance computing;
  • Using 360 Oncology care management to make multidisciplinary tumor boards smarter and more efficient;
  • Robust planning for proton therapy using the Eclipse system;
  • Multi-modality imaging in treatment planning, delivery and response assessment; and
  • First clinical impressions of HyperArc for treating brain metastases.

For more information: www.varian.com

Related Content

Videos | Radiation Therapy | February 15, 2019
ITN Associate Editor Jeff Zagoudis speaks with Vinai Gondi, M.D., director of research and CNS neuro-oncology at the
New Targeted Therapy for Recurrent Brain Tumors Implanted for First Time
News | Radiation Therapy | February 15, 2019
University of Minnesota Health (M Health) is the first in the United States to begin offering GammaTile Therapy, a new...
Canon Adds Radiation Therapy Package to Aquilion Prime, Lightning CT Systems
News | Computed Tomography (CT) | February 11, 2019
In the patient-centric world of radiation oncology, it is critical that computed tomography (CT) simulation is...
Elekta Unity MR-Linac Earns FDA Clearance
Technology | Image Guided Radiation Therapy (IGRT) | February 07, 2019
The Elekta Unity magnetic resonance radiation therapy (MR/RT) system recently received 510(k) premarket notification...
University of Oklahoma Cancer Center Begins First Proton Therapy Treatments
News | Proton Therapy | February 01, 2019
Home to the largest and most comprehensive radiation therapy program in Oklahoma, the Stephenson Cancer Center at OU (...
Stereotactic Radiotherapy Improves Long-Term Survival in Stage-IV Cancers
News | Stereotactic Body Radiation Therapy (SBRT) | January 31, 2019
The first report from a phase II, multi-center clinical trial indicates stereotactic radiation can extend long-term...
Philips Collaborates With MIM Software on Radiation Therapy Treatment Planning
News | Treatment Planning | January 31, 2019
January 31, 2019 — Philips announced a collaboration with imaging solutions provider MIM Software Inc.
Laurent Levy, CEO of Nanobiotix, explains the use of his company’s nanoparticles to enhance the radiation sensitivity of tumor tissue to improve patient outcomes

Laurent Levy, CEO of Nanobiotix, explains the use of his company’s nanoparticles to enhance the radiation sensitivity of tumor tissue to improve patient outcomes. The metallic-based nanoparticles show up on CT scans so it can be used as a permanent fiduciary marker to track tumor response. The images show the initial tumor and enhancement areas due to the nanoparticles and the resulting outcomes following treatment. Photo by Dave Fornell

Feature | Radiation Oncology | January 30, 2019 | By Dave Fornell
Artificial intelligence (AI) has been the hot topic discussed at all trade shows, and the...
Videos | Lung Cancer | January 29, 2019
Gregory Videtic, M.D., staff physician in radiation oncology at the Cleveland Clinic, and David Johnstone, M.D., prof
Southern Asia's First Proton Therapy Center Begins Treatments
News | Proton Therapy | January 28, 2019
IBA (Ion Beam Applications SA) announced the opening of the Apollo Proton Cancer Centre in Chennai, India, and the...